Evidence map›Paper›PMID 42172106›Full record

ArticleAnalytical chemistry2026

Dual Paper-Based Electrochemical Device for Multiplex Detection of Triple-Negative Breast Cancer miRNA Signatures.

Alessandra Glovi, Panagiota M Kalligosfyri, Antonella Miglione, Sima Singh, Wanda Cimmino, Stefania Cocco, Umberto Malapelle, Antonio Giordano, Michelino De Laurentiis, Stefano Cinti

Abstract read
In one paragraph

Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alessandra GloviClinical and Translational Oncology, Scuola Superiore Meridionale (SSM), Naples 80138, Italy.
Panagiota M KalligosfyriDepartment of Pharmacy, University of Naples Federico II, Naples 80131, Italy.ORCID 0000-0002-8287-059X
Antonella MiglioneDepartment of Public Health, University Federico II of Naples, Naples 80131, Italy.ORCID 0000-0002-7531-1159
Sima SinghDepartment of Pharmacy, University of Naples Federico II, Naples 80131, Italy.
Wanda CimminoDepartment of Pharmacy, University of Naples Federico II, Naples 80131, Italy.
Stefania CoccoDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples 80131, Italy.
Umberto MalapelleDepartment of Public Health, University Federico II of Naples, Naples 80131, Italy.
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, United States.
Michelino De LaurentiisDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples 80131, Italy.
Stefano CintiDepartment of Pharmacy, University of Naples Federico II, Naples 80131, Italy.ORCID 0000-0002-8274-7452

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this technical note, we demonstrate how the merging of paper-based screen-printing, engineered probes, and multiplexing might offer a potent tool toward the analysis of cancer-related miRNA signatures. In fact, while single miRNA detection cannot be associated with a health condition, the detection of miRNA signatures (more than one sequence) offers a more comprehensive reflection of disease biology. The two working electrodes are engineered with rationally designed capture probes modified with two different redox mediators, namely methylene blue and ferrocene; this is necessary to discriminate against different miRNAs, i.e., miRNA-21 and miRNA-101, which are dysregulated in triple-negative breast cancer. The use of ferrocene and methylene blue as redox mediators enables independent, interference-free target detection within a single electrochemical system. The analytical characterization of the dual sensor for both analytes is consistent with the single systems, enabling their simultaneous detection in a wide concentration range (0.1-1000 nM). The platform achieves clinically relevant low-nanomolar limits of detection in both PBS and untreated human serum, while demonstrating excellent repeatability with a relative standard deviation of ∼4%, a rapid assay time of 30 min and straightforward operational procedures. Importantly, the proof-of-concept analysis performed in untreated spiked serum samples demonstrated reliable detection within a complex biological matrix. These findings highlight the potential of multiplex miRNA signature analysis in biofluids and warrant further evaluation in clinically relevant samples. Overall, this fast, low-cost paper-based platform enables multiplex analysis at the point of care and can be readily expanded to larger miRNA panels, providing a promising foundation for future diagnostic development.

Indexed as

Electrochemical TechniquesMicroRNAsPaperTriple Negative Breast NeoplasmsBiosensing TechniquesElectrodesFemaleFerrous CompoundsHumansMetallocenesMethylene BlueferroceneFerrous CompoundsMetallocenesMethylene BlueMicroRNAs

Identifiers

PMID42172106
PMCPMC13261615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.